Elevated FGF21 and triglycerides in SLC25A13 carriers support the G3P-ChREBP Citrin Deficiency disease hypothesis

This study validates the G3P-ChREBP hypothesis for Citrin Deficiency by demonstrating that human carriers of SLC25A13 mutations exhibit elevated circulating FGF21 and a unique positive correlation between FGF21 and triglycerides, mirroring the metabolic dysfunction observed in mouse models.

The Gist

Imagine your body is a bustling, high-tech factory. Inside this factory, there's a specific delivery truck called Citrin (made by a gene called SLC25A13). This truck's job is to shuttle essential materials around the factory floor to keep everything running smoothly.

The Broken Truck Scenario

In some people, this Citrin truck is broken or missing entirely.

• The "Full" Factory (Citrin Deficiency): When the truck breaks, a specific material called G3P (think of it as a pile of raw sugar-cube ingredients) starts piling up in the factory's storage room.
• The Overactive Foreman (ChREBP): This pile of G3P triggers the factory foreman, named ChREBP, to go into overdrive. He starts shouting, "Make more fat! Make more fat!" This causes the factory to produce too much oil (triglycerides), leading to a condition where the liver gets greasy, even though the person is often very thin.
• The "No Sweets" Alarm (FGF21): At the same time, the factory sends out a distress signal called FGF21. In a normal factory, this signal usually tells the body to burn fat. But in this broken system, it acts like a giant "Do Not Eat Sugar" alarm bell. It makes people with this condition hate sweets and crave protein instead.

The Mouse vs. The Human Mystery

Scientists had already seen this exact chaos in mice with broken Citrin trucks. They knew the mice had high G3P, fat-laden livers, and a strong dislike for sugar. But they weren't sure if this "Broken Truck Theory" applied to humans, especially those who only had one broken truck (carriers) rather than two.

The Big Investigation

Researchers went to a massive database of people in Taiwan (the "Taiwan Biobank") to check if the human factory behaved like the mouse factory. They looked at people with:

1. Two broken trucks (full Citrin Deficiency).
2. One broken truck (carriers).
3. Working trucks (healthy controls).

What They Found

The results were like finding a smoking gun:

• The Alarm Bell is Loud: People with even just one broken truck had significantly higher levels of the distress signal (FGF21) in their blood compared to healthy people. It was like the factory was constantly ringing the "No Sweets" alarm, even if the truck wasn't completely gone.
• The Grease Connection: Here is the twist. In most people, high FGF21 usually means lower fat in the blood (because the body is burning it off). But in people with broken Citrin trucks, high FGF21 was linked to high fat (triglycerides).
  • Analogy: Imagine a fire alarm. In a normal building, the alarm means the fire is out. In this broken factory, the alarm is ringing because the fire (fat production) is raging out of control. The signal and the problem are stuck together.
• The Salt Clue: They also found these people were peeing out more salt, suggesting the "factory" was struggling to balance its fluids, another sign of the system being out of whack.

The Bottom Line

This study confirms that the "Broken Truck" theory isn't just a mouse story; it's a human reality. Even having just one broken Citrin truck changes how your body handles sugar and fat. It explains why some people naturally avoid sweets and why their livers might get greasy despite being thin.

In short: The body's "sugar-shunning" alarm and the "fat-making" machinery are both triggered by the same broken delivery truck, and this happens in humans just as it does in mice.

Technical Summary

Technical Summary: Elevated FGF21 and Triglycerides in SLC25A13 Carriers

1. Problem Statement
Citrin Deficiency (CD), caused by biallelic inactivation of the SLC25A13 gene, presents a unique metabolic paradox: patients exhibit lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) alongside a distinct behavioral aversion to sweets. While a murine model of CD (involving Slc25a13 and Gpd2 inactivation) suggested a mechanistic link involving elevated hepatic glycerol-3-phosphate (G3P) and the subsequent activation of the transcription factor ChREBP, this "G3P-ChREBP hypothesis" lacked validation in human populations. Specifically, it remained unproven whether heterozygous or homozygous SLC25A13 inactivation in humans leads to elevated circulating Fibroblast Growth Factor 21 (FGF21)—a potential driver of sweet aversion—and whether this elevation correlates with dyslipidemia (specifically triglycerides) in a manner consistent with the mouse model.

2. Methodology
The study utilized a human cohort approach leveraging the Taiwan Biobank, a large-scale genetic and phenotypic database.

• Cohort Selection: Researchers selected age- and sex-matched participants, categorizing them into control groups and SLC25A13 mutation carriers (heterozygous and homozygous/CD patients).
• Data Sources: Analysis focused on blood and urine samples.
• Key Variables:
  • Primary Biomarkers: Circulating FGF21 levels and urinary sodium.
  • Metabolic Correlates: Circulating lipid profiles, specifically triglycerides.
• Analytical Goal: To test the hypothesis that SLC25A13 inactivation elevates FGF21 and urinary sodium, and to determine if the correlation between FGF21 and triglycerides in carriers differs from the general population (where FGF21 typically suppresses lipids).

3. Key Contributions

• Human Validation of Mouse Models: This study provides the first direct human evidence supporting the G3P-ChREBP hypothesis derived from murine models, bridging the gap between animal mechanistic studies and human clinical phenotypes.
• Genotype-Phenotype Correlation: It establishes a dose-dependent relationship between SLC25A13 inactivation and metabolic dysregulation, showing that even heterozygous carriers exhibit significant metabolic deviations compared to controls.
• Paradoxical Lipid-FGF21 Relationship: The study identifies a unique metabolic signature in SLC25A13 carriers where the typical inverse relationship between FGF21 and triglycerides is reversed, suggesting a distinct pathophysiological driver in Citrin Deficiency.

4. Results

• Elevated FGF21 in Carriers:
  • Heterozygous Males: Showed a 2.2-fold increase in circulating FGF21 compared to controls (P = 0.056).
  • Heterozygous Females: Showed a 2.8-fold increase in circulating FGF21 compared to controls (P = 0.012).
  • CD Patients (Homozygous): Exhibited "greatly elevated" FGF21 levels.
• Urinary Sodium: Both CD patients and mutation carriers demonstrated significantly elevated urinary sodium excretion (P = 0.0052), indicating potential renal or systemic electrolyte handling changes associated with the mutation.
• FGF21 and Triglyceride Correlation:
  • In the general population, higher FGF21 is typically associated with lower circulating lipids.
  • In contrast, within the SLC25A13 carrier population, higher FGF21 was strongly correlated with higher circulating triglycerides. This supports the hypothesis that the same upstream driver (G3P accumulation) is simultaneously activating lipogenic transcription (via ChREBP) and FGF21 secretion.

5. Significance
The findings confirm that the loss of SLC25A13 function in humans drives a specific metabolic cascade characterized by simultaneous lipogenesis and FGF21 elevation. This dual effect provides a unified mechanistic explanation for the clinical presentation of Citrin Deficiency:

1. MASLD: Driven by ChREBP-mediated lipogenesis.
2. Sweet Aversion: Driven by elevated FGF21, which is known to induce carbohydrate aversion.

This study validates the translational relevance of the G3P-ChREBP mouse model and suggests that FGF21 could serve as a biomarker for identifying at-risk SLC25A13 carriers and understanding the metabolic basis of their liver disease and dietary preferences.